Bladder Cancer Clinical Trial
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.
This is a single arm, multi-part, phase 1/2 global trial studying TYRA-300, a novel, potent fibroblast growth factor receptor (FGFR) 3-selective tyrosine kinase inhibitor, in advanced/metastatic urothelial carcinoma of the bladder and urinary tract, that contain activating gene alterations of FGFR3. Phase 1 is a dose-escalation study to evaluate the safety, tolerability, and PK of TYRA-300 to determine the optimal and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Phase 2 will evaluate the preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.
Phase 1 Part A and Part B
Men and women 18 years of age or older.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
Histologically confirmed advanced solid tumor who have exhausted standard therapeutic options.
Evaluable (Part A) or measurable (Part B) disease according to RECIST v1.1.
Histologically confirmed advanced solid tumor with an eligible FGFR3 gene mutation or fusion (Part B).
Men and women 12 years of age or older.
ECOG performance status of 0-2 or Karnofsky Performance Scale (KPS) >70 for participants aged 12 to 17 years.
At least 1 measurable lesion by RECIST v1.1.
Histologically confirmed locally advanced/metastatic tumor in one of the following categories:
Urothelial carcinoma with an eligible FGFR3 gene mutation or rearrangement who have progressed on a prior FGFR inhibitor and presence of a resistance mutation or other kinase domain mutation.
Urothelial carcinoma with an eligible FGFR3 gene mutation or rearrangement who has not received a prior FGFR inhibitor.
Any solid tumor with an eligible FGFR3 gene mutation or rearrangement.
Exclusion Criteria (All Phases):
Has a serum phosphorus level > upper limit of normal (ULN) during screening that remains >ULN despite medical management.
Any ocular condition likely to increase the risk of eye toxicity.
History of or current uncontrolled cardiovascular disease.
Active, symptomatic, or untreated brain metastases.
Gastrointestinal disorders that will affect oral administration or absorption of TYRA-300.
Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 19 Locations for this study
Ocala Florida, 34474, United States More Info
Boston Massachusetts, 02215, United States More Info
New York New York, 10021, United States More Info
Durham North Carolina, 27710, United States More Info
Greenville South Carolina, 29605, United States More Info
Nashville Tennessee, 37232, United States More Info
Seattle Washington, 98109, United States More Info
Macquarie Park New South Wales, 2109, Australia More Info
Southport Queensland, 4215, Australia More Info
Woolloongabba Queensland, 4102, Australia More Info
Heidelberg Victoria, 3084, Australia More Info
Melbourne Victoria, 3000, Australia More Info
Nedlands Western Australia, 6009, Australia More Info
Saint Herblain , 44805, France More Info
Toulouse , 31059, France More Info
Villejuif , 94805, France More Info
Barcelona , 08023, Spain More Info
Barcelona , 08035, Spain More Info
Madrid , 28223, Spain More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.